Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib | Zendy

Ramona Dadu | Zendy; Catherine Devine | Zendy; Mike Hernández | Zendy; Steven G. Waguespack | Zendy; Naifa L. Busaidy | Zendy; Mimi I. Hu | Zendy; Camilo Jiménez | Zendy; Mouhammed Amir Habra | Zendy; Rena V. Sellin | Zendy; Anita K. Ying | Zendy; Gilbert J. Cote | Zendy; Steven I. Sherman | Zendy; Maria E. Cabanillas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib

Author(s) -

Ramona Dadu,

Catherine Devine,

Mike Hernández,

Steven G. Waguespack,

Naifa L. Busaidy,

Mimi I. Hu,

Camilo Jiménez,

Mouhammed Amir Habra,

Rena V. Sellin,

Anita K. Ying,

Gilbert J. Cote,

Steven I. Sherman,

Maria E. Cabanillas

Publication year - 2014

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2013-3588

Subject(s) - sorafenib , medicine , salvage therapy , thyroid cancer , oncology , progressive disease , retrospective cohort study , surgery , cancer , gastroenterology , chemotherapy , hepatocellular carcinoma

Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research